Which companies overlap with Jiangsu Province Centers for Disease Control and Prevention's portfolio?

Top competitors by shared drug class: Sanofi Pasteur, a Sanofi Company, Merck Sharp & Dohme LLC, GlaxoSmithKline, Sinovac Biotech Co., Ltd, Sanofi.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/jiangsu-province-centers-for-disease-control-and-prevention.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-18 · How we verify

Jiangsu Province Centers for Disease Control and Prevention — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Jiangsu Province Centers for Disease Control and Prevention pipeline: 15 marketed, 0 filed, 12 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

15 marketed 0 filed 12 Phase 3 2 Phase 2 3 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Ad5-nCoV-IH	Ad5-nCoV-IH	marketed
23vPPV+TIV	23vPPV+TIV	marketed	Combination vaccine		Immunology / Infectious Disease
batch 1 of Ad5-nCoV	batch 1 of Ad5-nCoV	marketed	viral vector vaccine	SARS-CoV-2 spike protein	Immunology / Infectious Disease
batch 2 of Ad5-nCoV	batch 2 of Ad5-nCoV	marketed
Ad5-nCoV-IM	Ad5-nCoV-IM	marketed
Aerosolized Ad5-nCoV	Aerosolized Ad5-nCoV	marketed
Standard dosage inactivated vaccine	Standard dosage inactivated vaccine	marketed
Attenuated Hepatitis A Vaccine, H2 Strain	Attenuated Hepatitis A Vaccine, H2 Strain	marketed	Live attenuated vaccine	Hepatitis A virus	Immunology
SYS6006	SYS6006	marketed			Oncology
Double dosage inactivated vaccine	Double dosage inactivated vaccine	marketed
Recombinant SARS-CoV-2 Ad5 vectored vaccine	Recombinant SARS-CoV-2 Ad5 vectored vaccine	marketed
A+C Vaccine	A+C Vaccine	marketed	Polysaccharide conjugate vaccine	Neisseria meningitidis serogroups A and C polysaccharide capsule	Immunology / Infectious Disease

Therapeutic area mix

Immunology · 9
Immunology / Infectious Disease · 7
Infectious Disease · 2
Oncology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Sanofi Pasteur, a Sanofi Company · 7 shared drug classes
Merck Sharp & Dohme LLC · 6 shared drug classes
GlaxoSmithKline · 6 shared drug classes
Sinovac Biotech Co., Ltd · 5 shared drug classes
Sanofi · 5 shared drug classes
PT Bio Farma · 4 shared drug classes
PATH · 4 shared drug classes
Pfizer · 4 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Jiangsu Province Centers for Disease Control and Prevention:

Cite this brief

Drug Landscape (2026). Jiangsu Province Centers for Disease Control and Prevention — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/jiangsu-province-centers-for-disease-control-and-prevention. Accessed 2026-05-18.